- $500.80bn
- $565.10bn
- $61.16bn
Brief: Abbvie - Q3 2026 GAAP And Adjusted Earnings Include $216 Million Bought Ipr&D And Milestones Expense - SEC Filing
AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
AbbVie joins US government pilot to test drug discount rebates
Brief: Abbvie Says Phase 3 Studies Show Continued Repigmentation With Rinvoq Through Week 76
Brief: AbbVie Says Phase 1 ABBV-295 Study Shows Mean Weight Loss Up To About 10% Over 3-Month Period
Factbox: Pharma sector doubles down on AI to slash costs, timelines
US FDA approves AbbVie's drug for Parkinson's disease (updated)
US FDA approves AbbVie's drug for Parkinson's disease
ADARx Pharmaceuticals surges in Nasdaq debut after upsized $446.3 million IPO
ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO (updated)
ADARx Pharmaceuticals set to open higher in Nasdaq debut after upsized $446.3 million IPO
ADARx Pharmaceuticals raises $446.3 million in upsized US IPO
Brief: Epkinly Receives Health Canada Approval For Adults With Follicular Lymphoma
Live Markets: RBC says AI weakness appears to be fueling biotech rally
Oruka falls after reporting mid-stage data for psoriasis drug
Brief: AbbVie Announces European Commission Approval Of RINVOQ (Upadacitinib)
Brief: AbbVie And Iambic Announce Collaboration To Accelerate AI-Driven Drug Discovery
Brief: Adarx Pharmaceuticals: IPO Price Expected Between $15 And $17 Per Share
Drug developer ADARx seeks $1.74 billion valuation in US IPO (updated)